322 related articles for article (PubMed ID: 22467630)
1. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
Zhanel GG; Yachison C; Nichol K; Adam H; Noreddin AM; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2012 Jul; 67(7):1706-11. PubMed ID: 22467630
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.
Steed ME; Vidaillac C; Winterfield P; Biek D; Rybak MJ
Antimicrob Agents Chemother; 2012 May; 56(5):2691-5. PubMed ID: 22354289
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
[TBL] [Abstract][Full Text] [Related]
9. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
[TBL] [Abstract][Full Text] [Related]
10. Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08).
Morrissey I; Leakey A
J Antimicrob Chemother; 2012 Jun; 67(6):1408-12. PubMed ID: 22357801
[TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
Gosbell IB; Fernandes LA; Fernandes CJ
Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
[TBL] [Abstract][Full Text] [Related]
12. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
Knudsen JD
Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Biek D; Critchley IA; Riccobene TA; Thye DA
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
[TBL] [Abstract][Full Text] [Related]
14. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae.
Moisan H; Pruneau M; Malouin F
J Antimicrob Chemother; 2010 Apr; 65(4):713-6. PubMed ID: 20097788
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
[TBL] [Abstract][Full Text] [Related]
16. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae.
Cha R; Rybak MJ
J Antimicrob Chemother; 2004 Dec; 54(6):1067-71. PubMed ID: 15486084
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
[TBL] [Abstract][Full Text] [Related]
18. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Morrissey I; Ge Y; Janes R
Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
Odenholt I; Cars O; Löwdin E
J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
McGee L; Biek D; Ge Y; Klugman M; du Plessis M; Smith AM; Beall B; Whitney CG; Klugman KP
Antimicrob Agents Chemother; 2009 Feb; 53(2):552-6. PubMed ID: 19015339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
